The most advanced space in the global pharma arena is Biosimilars. This is where cutting edge innovation is providing Superior Biosimilar products covering a wide range of indications/uses.
Keeping in line with our commitment to innovation, we have entered into a JV with Regenix Group to set up a Greenfield Biosimilar Injectable facility in the name of Regenix Biosciences Ltd. The plant has been designed and implemented adhering to the EMA Guidelines with a high level of automation and a fully compliant laboratory to start commercial rollout in Q3 2022.
